MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
BioNano Genomics Market Cap 2011-2026 | BNGO
As of April 19, 2026 BioNano Genomics has a market cap of $ 7.02 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.95 M | 3.55 M | 683 K | 37 M | 614 M | 1.47 B | 37.4 M | 40.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 B | 683 K | 276 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 29.7 | 3.74 % | $ 20 B |  Niderland |
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
42 B | $ 121.87 | 3.06 % | $ 37 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 20.67 | -8.13 % | $ 222 M |  China |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 21.42 | -4.46 % | $ 1.14 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.56 | 6.85 % | $ 2.08 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 25.05 | 2.0 % | $ 696 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 183.88 | 3.92 % | $ 9.11 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 194.75 | 0.5 % | $ 139 B | USA |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 2.0 | -9.09 % | $ 8.85 M | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 5.08 | 1.6 % | $ 470 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.35 | 2.33 % | $ 1.07 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.51 | 2.92 % | $ 2.06 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 520.6 | 0.96 % | $ 15 B | USA |
 |
Illumina
ILMN
|
16.4 B | $ 134.5 | 1.34 % | $ 21.4 B | USA |
 |
Precipio
PRPO
|
38.4 M | $ 28.3 | -2.41 % | $ 45.4 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 16.26 | 0.81 % | $ 492 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 90.36 | 5.44 % | $ 11.3 B | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 6.77 | - | $ 282 M | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.91 | 2.83 % | $ 94.4 K | USA |
 |
Soleno Therapeutics
SLNO
|
2.08 B | $ 52.78 | 0.4 % | $ 2.68 B | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.18 | -0.91 % | $ 5.01 M | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 119.68 | 3.55 % | $ 9.87 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 270.68 | 1.62 % | $ 22.5 B | USA |
 |
Neuronetics
STIM
|
81.1 M | $ 1.42 | 1.43 % | $ 93.7 M | USA |
 |
Celcuity
CELC
|
5.37 B | $ 122.46 | -2.23 % | $ 5.73 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 83.82 | -0.12 % | $ 5.66 B | USA |
 |
Thermo Fisher Scientific
TMO
|
196 B | $ 526.6 | 2.05 % | $ 199 B | USA |
 |
Trinity Biotech plc
TRIB
|
120 M | $ 0.75 | 6.62 % | $ 61.9 M | Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 195.02 | 1.86 % | $ 21.6 B | USA |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 6.4 | 23.79 % | $ 5.04 M | USA |